Lung Cancer

Edward B. Garon, MD, discusses immunotherapy treatment considerations for patients with non–small cell lung cancer.

Nisha A. Mohindra, MD, discusses the integration of lurbinectedin into the small cell lung cancer paradigm and remaining questions regarding future therapeutic directions.

Discussion on the FDA approval of capmatinib, a MET inhibitor, as treatment for patients with MET exon 14-mutated non–small cell lung cancer based on data demonstrated by the GEOMETRY mono-1 study.

Recommendations for using next-generations sequencing panels as well as liquid biopsies to help identify MET exon 14 skipping mutations and other oncogenic drivers in patients with non–small cell lung cancer.

Wade T. Iams, MD, discusses the efficacy and safety of lurbinectedin in patients with small cell lung cancer, the impact of its approval on the paradigm, and remaining questions regarding its use.

Janakiraman Subramanian, MD, discusses the efficacy of selpercatinib in patients with RET fusion–positive non–small cell lung cancer.

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Considerations for second-line treatment regimens, the role of immunotherapy in the relapsed/refractory setting, and using lurbinectedin for the management of ES-SCLC.

Stephen V. Liu, MD, and Jared Weiss, MD, share their thoughts on the impact of the recent approval of trilaciclib prior to platinum/etoposide-based chemotherapy for the treatment of ES-SCLC.

The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.

Jason Porter, MD, discusses potential sequencing strategies with antibody-drug conjugates and TKIs in HER2-positive lung cancer.

Lyudmila A. Bazhenova, MD, discusses the importance of testing for HER2 mutations in lung cancer.

Luis E. Raez, MD, discusses the impact of PD-L1 status on immunotherapy outcomes for patients with non–small cell lung cancer.

Antoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.

Dr. Hu discusses the importance of testing for RET alterations in thyroid cancer, the FDA approvals of selpercatinib and pralsetinib, and the changing dynamics between medical oncologists and endocrinologists.

Melissa L. Johnson, MD, discusses the clinical potential of AMG 757 in patients with small cell lung cancer.

Drs Joshua M. Bauml and Benjamin Levy react to the development of novel therapies that specifically target MET exon 14 skipping mutations in non–small cell lung cancer.

Drs Joshua M. Bauml and Lyudmila A. Bazhenova describe what is understood regarding the behavior of MET exon 14 skipping mutations in non–small cell lung cancer and remark on their prevalence among specific patient populations.

Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses treatment after osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.

Janakiraman Subramanian, MD, discusses the use of EGFR TKIs in the treatment of patients with non–small cell lung cancer.

Osimertinib (Tagrisso) showcased encouraging efficacy and acceptable safety in patients with EGFR-positive, advanced non–small cell lung cancer. according to real-world findings from an observational, multicenter study.

Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.